860627P

C18 Dihydroceramide (d18:0/18:0)

Avanti Research^™ - A Croda Brand 860627P, powder

• Synonym(e): N-stearoyl-D-erythro-sphinganine
• Empirische Formel (Hill-System): C₃₆H₇₃NO₃
• CAS-Nummer: 2304-80-5
• Molekulargewicht: 567.97
• UNSPSC-Code: 12352211
• NACRES: NA.25

Eigenschaften

• Form: powder
• Verpackung: pkg of 1 × 25 mg (860627P-25mg); pkg of 1 × 5 mg (860627P-5mg)
• Hersteller/Markenname: Avanti Research^™ - A Croda Brand 860627P
• Lipid-Typ: sphingolipids
• Versandbedingung: dry ice
• Lagertemp.: −20°C
• SMILES String: OC[C@]([H])(NC(CCCCCCCCCCCCCCCCC)=O)[C@]([H])(O)CCCCCCCCCCCCCCC
• InChI: 1S/C36H73NO3/c1-3-5-7-9-11-13-15-17-18-20-22-24-26-28-30-32-36(40)37-34(33-38)35(39)31-29-27-25-23-21-19-16-14-12-10-8-6-4-2/h34-35,38-39H,3-33H2,1-2H3,(H,37,40)/t34-,35+/m0/s1
• InChIKey: KZTJQXAANJHSCE-OIDHKYIRSA-N

Beschreibung

Allgemeine Beschreibung

C18 Dihydroceramide (d18:0/18:0) or N-Stearoylsphinganine is a synthetic lipid. Acylation of sphinganine with stearoyl (FA-CoA with C18 acyl chain) by dihydro ceramide synthase 1, yields C18-dihydroceramide.

Anwendung

C18 Dihydroceramide (d18:0/18:0) has been used as a standard for the quantitation of sphingolipid metabolites in adipose tissues by quadrupole time-of-flight (Q-TOF) mass spectrometry.

Biochem./physiol. Wirkung

Dihydroceramides act as precursors for ceramides in the mammalian de-novo sphingolipid pathway. vitamin D supplementation increases plasma C18 dihydroceramide (C18-DHC) levels in type 2 diabetes mellitus (T2D) patients. Low serum concentration of C18-DHC has been observed in patients with history of graft rejection and ischemic type biliary lesions (ITBL). Therefore, it can be used as a predictor of graft rejection.

Verpackung

5 mL Amber Glass Screw Cap Vial (860627P-25mg)

5 mL Amber Glass Screw Cap Vial (860627P-5mg)

Rechtliche Hinweise

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids